INTRODUCTION

Overall situation

An “epidemic” in the use of opioids in the USA and other countries, including European ones, has been reported in the last 15 years [1-6]. Several scientific and governmental institutes bodies deal with this issue, including the Atlanta CDC (Center of Disease Control) that detected an increased number of deaths due to opioids use between 2014 and 2015 [7, 8]. One of the reasons is that patients, who begin to take opioids for pain therapy after surgery (postoperative analgesia), may develop an “addiction” when the treatment becomes chronic [9], i.e. when it lasts for more than three months [10]. American scientific and governmental bodies, that analysed this issue, agreed upon the need to set up national and supranational registers including prescription and consumption of opioids (which were difficult to establish in the USA) as well as the need for specific laws and guidelines regarding opioids prescriptions [11]. The main corrective actions were assisted by the ASIPP (American Society of Interventional Pain Physicians) through the establishment of a national register of prescriptions (NASPER – National All Schedules Prescription Electronic Reporting Act), however with limitations that relegated it to single states in the US and not to the whole country [12]. From a regulatory point of view, ASIPP established collaborations with the Atlanta CDC, the NIDA (National Institute on Drug Abuse) and the FDA (Food and Drug Administration) in order to guarantee appropriate prescription by physicians along with the promotion of a correct education in patients in treatment with opioids [13-15].

Risk of addiction

Based on several surveys (principally carried out in the USA), the risk of addiction seems to develop when...
prescribed doses exceed 40-50 mg MED (Morphine Equivalent Dose in milligrams) a day [11]. Another parameter as the average pro capita a year being 144 MED in Italy, is far below the average of 693 MED a year in the USA and other European and non-European countries (taking in consideration the six most common opioids) [11].

The aim of the study
This study aims to assess if there is a risk of addiction for Italian patients suffering from chronic cancer and non-cancer pain, who undergo chronic pain therapy with opioids, based on a previous Italian study that defined which patients are to be considered chronic opioids users [16]. In that paper, Authors analysed a yearly Italian opioids prescription database with the aim to determine, with a specific algorithm, chronic cancer and non-cancer opioids users. With this in mind, we began analysing the same previous database of Italian Ministry of Health [16] regarding the prescription of opioids for pain management, to determine potentially addictive behaviours.

METHODS
The population of the study
All opioid prescriptions covered by the National Health System in 2013 were collected anonymously. Patients with at least one prescription of an opioid a month for three consecutive months and/or six non-consecutive months in the reporting period (from 1 January to 31 December) were considered chronic. Cancer patients were those who entitled to exemption code 048 (“malignant neoplastic disease”) or the ones who were given ROOs (Rapid Onset Opioids; drugs that can only be prescribed to cancer patients in Italy).

Opioids requirements
Analysing the encrypted identification codes of the patients, we examined the attitude of prescriptions for each cancer and non-cancer patient. The amount of required opiates for any patient was transformed into daily MED. The MED is calculated using a specific conversion tool to pass from any opioid prescribed to morphine equivalent dosage [17]. We excluded the first three months of therapy, as a period of dosage adjustment. Starting from the fourth month (our baseline), we considered every monthly percentage increase of MED during the entire period of chronic therapy.

Statistical analysis
The patients were subdivided into classes of the percentage increase or decrease from the baseline value. We compared the results of cancer and non-cancer patients through two unpaired Student t-test samples. P values < 0.05 were considered significant.

RESULTS
Based on previous study referring to the same database [16] in Italy 422,542 patients were found to be on chronic opioid therapy in 2013, of which 52,581 were cancer patients (with ticket exemption code number 048 – “malignant neoplastic disease”). The following specific analysis of the database shows in Table 1 the classes of mean dosage increase/decrease for all the patients considered as a unique cluster on chronic therapy and then distinguishes between cancer and non-cancer ones. Figure 1 shows the numbers of total patients, cancer and non-cancer ones, in each incremental class. Figure 2 represents the percentage increase in MED of opioids for all patients, cancer and non-cancer ones. Looking at both figures, we deduce that small proportions of decrease or increase prevailed in the reporting period. Cancer patients had a greater percentage of increases, although they were not statistically significant (p-value > 0.05). The mean MED for each patient is already described in a previous work [16].

DISCUSSION
Opioids increase rate
Our results did not show an excessive dosage increase in patients on chronic therapy with opioids in Italy during the observational period (patients mainly had a decrease or only a modest increase in their dosage). Despite not having an international database to compare to, this probably means that the American opioid epidemic did not involve Italy. This situation could be due to the Italian law 38/2010 [18] which, for the first time in Europe and one of the first times in the world, regulated the clinical practice regarding opioid therapy for patients suffering from chronic pain. In particular, it facilitates opioid prescription when necessary, meanwhile creating a culture of knowledge for healthcare professionals and instruments of control.

Table 1
Opioids morphine equivalent dose (MED) increase rate in chronic pain patients

<table>
<thead>
<tr>
<th>Classes of MED increase (%)</th>
<th>Total patients</th>
<th>Non-cancer patients</th>
<th>Cancer patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;0</td>
<td>131,316</td>
<td>112,358</td>
<td>18,958</td>
</tr>
<tr>
<td>0-10</td>
<td>125,055</td>
<td>115,108</td>
<td>9,947</td>
</tr>
<tr>
<td>10-20</td>
<td>33,718</td>
<td>29,996</td>
<td>3,722</td>
</tr>
<tr>
<td>20-30</td>
<td>29,070</td>
<td>25,127</td>
<td>3,943</td>
</tr>
<tr>
<td>30-40</td>
<td>26,789</td>
<td>24,307</td>
<td>2,482</td>
</tr>
<tr>
<td>40-50</td>
<td>31,014</td>
<td>27,077</td>
<td>3,937</td>
</tr>
<tr>
<td>50-60</td>
<td>8,366</td>
<td>6,459</td>
<td>1,907</td>
</tr>
<tr>
<td>60-70</td>
<td>9,633</td>
<td>7,769</td>
<td>1,864</td>
</tr>
<tr>
<td>70-80</td>
<td>6,802</td>
<td>5,549</td>
<td>1,253</td>
</tr>
<tr>
<td>80-90</td>
<td>4,943</td>
<td>3,699</td>
<td>1,244</td>
</tr>
<tr>
<td>90-100</td>
<td>4,436</td>
<td>3,699</td>
<td>737</td>
</tr>
<tr>
<td>100-110</td>
<td>1,690</td>
<td>1,479</td>
<td>211</td>
</tr>
<tr>
<td>110-120</td>
<td>1,521</td>
<td>1,349</td>
<td>172</td>
</tr>
<tr>
<td>120-130</td>
<td>1,309</td>
<td>1,109</td>
<td>200</td>
</tr>
<tr>
<td>130-140</td>
<td>1,309</td>
<td>1,109</td>
<td>200</td>
</tr>
<tr>
<td>140-150</td>
<td>1,014</td>
<td>739</td>
<td>275</td>
</tr>
<tr>
<td>150-200</td>
<td>2,915</td>
<td>2,219</td>
<td>696</td>
</tr>
<tr>
<td>&gt;200</td>
<td>1,642</td>
<td>809</td>
<td>833</td>
</tr>
<tr>
<td>Total</td>
<td>422,542</td>
<td>369,961</td>
<td>52,581</td>
</tr>
</tbody>
</table>
Figure 1
Number of patients in each class of percent increase in daily MED of opioids.

Figure 2
Percentage of patients in each incremental class of daily MED of opioids.
in order to ensure a constant appropriate prescription. This seems to prevent the development of the phenomenon of addiction in chronic patients. Other preliminary studies [16] proved that daily MED prescribed to non-cancer patients (30,13 mg) are lower than the baseline values of 40-50 mg/day that are considered to cause addiction by the American scientific society [1]. A recent analysis published on Pain [9] indicated how the starting dosage for patients who would receive chronic therapy in some American analgesic treatment centres (55 mg/day that would increase to 83 mg/day) was higher than the average dosage observed in Italy. This difference may primarily be due to the Italian law 38/2010 that created a “hub & spoke” organisation for the control and management of opioids, and secondly due to where the analysis took place in consideration that in the USA the analysis was done in specific analgesic treatment centres.

Situation in Italy

In Italy all the prescriptions we considered, including those from general practitioners who might tend to start with lower doses due to lack of experience in the field of pain care. Recently we also considered cancer patients with long survival as patients potentially subject to addiction on the heels of the American “plague”. The average dosage in daily MED in Italian patients (79.47 mg) was coherent with an other international analysis that reported an average of 80 mg/day [19] in cancer patients.

Risk of addiction

Our analysis showed that neither a risk of addiction nor an indication to limit opioid therapy in these patients seems to exist, being in accordance with recent publications [20].

CONCLUSIONS

The opioids “plague” that is striking the USA has not struck Italy. The reasons might be due to the innovative and effective law 38/2010 together with a health care system able to guarantee appropriate prescriptions for major analgesics. Nevertheless, it might be useful to continue the ministerial monitoring carried out in 2013, with the aim to identify any aberration in opioid prescriptions.

Acknowledgements

The authors wish to thank the Italian Ministry of Health, Department of digitalisation and statistics.

Author contributions

The authors contributed equally in study design, data analysis and interpretation and paper drafting.

Conflict of interest statement

The authors declare no conflict of interest, no funding resources.

Received on 20 April 2018.
Accepted on 31 July 2018.

REFERENCES


